fda warning letters compounded semaglutide tirzepatide 2025 Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding FDA issued 25 warning letters

A GLP-1 agonist like semaglutide activates one receptor to suppress appetite and improve blood sugar

GLP-1 receptors (GLP-1R) are G-protein coupled receptors predominantly located in pancreatic cells, which underpins their role in glucose homeostasis

Since obesity is considered a chronic condition, many individuals may require continued care to achieve sustained weight loss and its associated health benefits 13

First-month prices in ads, real costs buried in FAQ, and a checkout flow that obscures rather than clarifies all hide details

[DOI] [PMC free article] [PubMed] [Google Scholar] 140.Lee J.-H., Lee J

I felt like I had to lean in to try and capture what was missing, but it was to no avail